| Australia's wine industry: collaboration and learning as causes of competitive success I Marsh, B Shaw Australian Business Foundation, 2000 | 72 | 2000 |
| Ethics and compliance in global pharmaceutical industry marketing and promotion: The role of the IFPMA and self-regulation B Shaw, P Whitney Pharmaceuticals Policy and Law 18 (1-4), 199-206, 2016 | 48 | 2016 |
| Creeping through the backdoor: disruption in medicine and health B Shaw, O Chisholm Frontiers in Pharmacology 11, 818, 2020 | 33 | 2020 |
| Talkin’about a resolution: issues in the push for greater transparency of medicine prices B Shaw, J Mestre-Ferrandiz Pharmacoeconomics 38 (2), 125-134, 2020 | 28 | 2020 |
| Policy instruments ( non-price) for medical innovation J Mestre-Ferrandiz, B Shaw, C Chatterjee, J Ding, P Singh, MM Hopkins World Health Organization, 2022 | 6 | 2022 |
| Economic governance and a coordination rational for the state: the case of industry policy B Shaw, OE Hughes Economic governance and institutional dynamics, 200-225, 2002 | 6 | 2002 |
| Collaboration and learning in Australia's wine industry. Performance impacts and industry implications. I Marsh, B Shaw | 6 | 1999 |
| Australia's wine industry I Marsh, B Shaw Australian Business Foundation, 2000 | 5 | 2000 |
| Australia’s National Medicines Policy is outdated and in need of review B Shaw, O Chisholm Medicine 8, 2018, 2019 | 4 | 2019 |
| Exports, export culture and the Australian economy B Shaw, O Hughes Department of Management, Faculty of Business and Economics, Monash University, 2001 | 4 | 2001 |
| A critique of the paper “The estimated costs of production and potential prices for the World Health Organization Essential Medicines List” A Towse, K Hernandez-Villafuerte, B Shaw Office of Health Economics, 2018 | 3 | 2018 |
| Biosimilars naming and prescribing policy in Australia B Shaw Generics and Biosimilars Initiative Journal (GaBI Journal) 2 (4), 168-9, 2013 | 3 | 2013 |
| Deferring PBAC decisions: industry view B Shaw Australian Prescriber 35 (1), 2012 | 3 | 2012 |
| The Export Market Development Grants Scheme and the Development of Australian Exports: Rationale, Impact and Recommendations B Shaw, O Hughes Department of Management Working Paper, Monash University, 2004 | 2 | 2004 |
| Australia¶ s Wine Industry: Collaboration and Learning As Causes of Competitive Success M Ian, S Brendan Australian Business Foundation, Mayıs, 2000 | 2 | 2000 |
| HPR105 Profitability in the Global Pharmaceutical Industry: A Contested Space B Shaw, J Mestre-Ferrandiz, EK Wassink Value in Health 26 (12), S272, 2023 | | 2023 |
| Innovation policy instruments (non-price) for medical innovation. Web-Annex: innovation policy instruments for new medicines J Mestre-Ferrandiz, B Shaw, C Chatterjee, J Ding, P Singh, MM Hopkins Innovation policy instruments (non-price) for medical innovation. Web-Annex …, 2022 | | 2022 |
| Инструменты политики (не связанные с ценовыми факторами) в поддержку инноваций в области медицины: Технический доклад Инициативы Осло по лекарственным средствам: основные … B Shaw, C Chatterjee, J Ding, P Singh, MM Hopkins, J Mestre-Ferrandiz Всемирная организация здравоохранения. Европейское региональное бюро, 2022 | | 2022 |
| A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List” K Hernandez-Villafuerte, B Shaw, A Towse Contract Research, 2018 | | 2018 |
| Medicines Australia Code of Conduct B Shaw AUSTRALIAN PRESCRIBER 33 (4), 101-101, 2010 | | 2010 |
